Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Avalo Therapeutics Inc AVTX

Healthcare Biotechnology
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1ß mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1ß (IL-1ß... see more

Recent & Breaking News (NDAQ:AVTX)

Cerecor Appoints Gilla Kaplan, Ph.D., to the Board of Directors

GlobeNewswire October 12, 2020

Cerecor to Present at Upcoming Investor Conferences

GlobeNewswire September 10, 2020

Cerecor Resumes Phase 1b Clinical Trial of CERC-002 for the Treatment of Severe Pediatric Onset Crohn's Disease

GlobeNewswire August 26, 2020

Cerecor Announces Peer-Reviewed Publication Highlighting the Role of the Inflammatory Cytokine, LIGHT, in COVID-19 ARDS

GlobeNewswire August 13, 2020

Cerecor Reports Second Quarter 2020 Financial Results and Business Update

GlobeNewswire August 6, 2020

Cerecor to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

GlobeNewswire August 5, 2020

Cerecor Receives Rare Pediatric Disease Designation for CERC-006 in Lymphatic Malformations

GlobeNewswire August 4, 2020

Cerecor Receives Orphan Drug Designation for CERC-006 in Lymphatic Malformations

GlobeNewswire August 3, 2020

Cerecor Announces First Patient Enrolled in Multicenter Proof-of-Concept Study Evaluating CERC-002 for COVID-19 ARDS

GlobeNewswire July 21, 2020

Cerecor Inc. Announces Closing of $37.95 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares

GlobeNewswire June 11, 2020

Cerecor Inc. Announces Pricing of $33,000,000 Public Offering of Common Stock

GlobeNewswire June 9, 2020

Cerecor Inc. Announces Proposed Public Offering of Common Stock

GlobeNewswire June 8, 2020

Cerecor to Present at the Jefferies Virtual Healthcare Conference

GlobeNewswire May 29, 2020

Cerecor Announces FDA Clearance of IND for CERC-002 in COVID-19 Induced ARDS

GlobeNewswire May 28, 2020

Cerecor and Myriad Genetics Announce that Levels of LIGHT, a Novel Cytokine, Were Highly Correlated with Disease Severity and Mortality in COVID-19 ARDS Biomarker Study

GlobeNewswire May 26, 2020

Cerecor Reports Q1 2020 Results and Update

GlobeNewswire May 7, 2020

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Cerecor Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

PR Newswire May 4, 2020

Cerecor Announces Changes to Board of Directors

GlobeNewswire April 24, 2020

Cerecor Announces Exploration of the Role of an Inflammatory Cytokine, LIGHT, in COVID-19 Patients with Acute Lung Injury Leading to Acute Respiratory Distress Syndrome

GlobeNewswire March 26, 2020

Cerecor Reports 2019 Results

GlobeNewswire March 11, 2020